

# J Andrew Livingston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3035603/publications.pdf>

Version: 2024-02-01

48  
papers

1,060  
citations

516710

16  
h-index

454955

30  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1784  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. <i>Nature Communications</i> , 2022, 13, 42.	12.8	27
2	Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. <i>Oncologist</i> , 2022, 27, 135-143.	3.7	3
3	Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. <i>Advances in Radiation Oncology</i> , 2022, 7, 100913.	1.2	4
4	Factors impacting adolescent and young adult cancer patientsâ€™ decision to pursue genetic counseling and testing. <i>Supportive Care in Cancer</i> , 2022, 30, 5481-5489.	2.2	2
5	Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. <i>Cancer Medicine</i> , 2022, 11, 3471-3478.	2.8	7
6	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1176-1184.	2.5	6
7	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	14
8	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskelatal Ewing Sarcoma. <i>Oncologist</i> , 2021, 26, 250-260.	3.7	9
9	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. <i>Cell Reports</i> , 2021, 34, 108678.	6.4	33
10	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. <i>Cancer Gene Therapy</i> , 2021, 28, 1325-1338.	4.6	13
11	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 164-174.	1.3	8
12	Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11575-TPS11575.	1.6	4
13	Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1717-1725.	2.5	15
14	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1496-1504.	0.8	11
15	Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. <i>Cancer Epidemiology</i> , 2021, 75, 102044.	1.9	5
16	Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 5249.	3.7	4
17	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. <i>Sarcoma</i> , 2020, 2020, 1-6.	1.3	16
18	Genomics and the Immune Landscape of Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1258, 21-36.	1.6	31

#	ARTICLE	IF	CITATIONS
19	Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. <i>Clinical Sarcoma Research</i> , 2020, 10, 14.	2.3	11
20	Long-term survival among 5-year survivors of adolescent and young adult cancer. <i>Cancer</i> , 2020, 126, 3708-3718.	4.1	33
21	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	3.7	20
22	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	12.8	143
23	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 812-822.	6.4	11
24	A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11509-11509.	1.6	13
25	A phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3645-TPS3645.	1.6	1
26	Improving Outcomes for Adolescents and Young Adults With Sarcoma: A Focus on Cancer Care Delivery. <i>Journal of Oncology Practice</i> , 2019, 15, 253-254.	2.5	3
27	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. <i>Cancers</i> , 2019, 11, 1283.	3.7	19
28	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019, 11, 677.	3.7	20
29	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 385-386.	1.3	4
30	Extraskeletal Osteosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 238-242.	1.3	6
31	Extraskeletal Myxoid Chondrosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 744-748.	1.3	11
32	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11010-11010.	1.6	6
33	Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 66-97.	4.9	206
34	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1315-1323.	4.1	13
35	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018, 20, 37.	4.0	27
36	Emergency Department Visits by Adolescent and Young Adult Cancer Patients Compared with Pediatric Cancer Patients in the United States. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 553-564.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 681-687.	1.3	14
38	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. <i>Oncotarget</i> , 2018, 9, 1602-1616.	1.8	15
39	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10520-10520.	1.6	0
40	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11522-11522.	1.6	0
41	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Scientific Reports</i> , 2017, 7, 11836.	3.3	57
42	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	3.7	20
43	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , 2017, 7, 11.	2.3	61
44	Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26318.	1.5	15
45	Chemotherapy for Bone Sarcoma in Adults. <i>Journal of Oncology Practice</i> , 2016, 12, 208-216.	2.5	44
46	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016, 7, 64421-64430.	1.8	17
47	Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e656-e660.	3.8	13
48	3D tissue-engineered model of Ewing's sarcoma. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 155-171.	13.7	39